{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-169947","form_type":"8-K","ticker":"INDV","cik":"0001625297","company_name":"Indivior Pharmaceuticals, Inc.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.511221+00:00","generated_at":"2026-05-17T22:20:02.526590+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Indivior raises FY 2025 guidance after Q2 beat; SUBLOCADE revenue up 9%","bullets":["Q2 total net revenue $302M (+1% YoY); net income $18M ($0.14 EPS); non-GAAP diluted EPS $0.51.","SUBLOCADE net revenue $209M (+9% YoY, +19% vs Q1'25); U.S. SUBLOCADE $195M (+9% YoY).","FY 2025 guidance raised: net revenue $1.03B-$1.08B (prior $955M-$1.025B); adjusted EBITDA $275M-$300M (prior $220M-$260M).","Adjusted EBITDA Q2 $88M vs $93M Q2'24; cash and investments $538M at Q2 end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-169947","json":"https://secwatch.observer/filing/0001193125-25-169947.json","markdown":"https://secwatch.observer/filing/0001193125-25-169947.md","text":"https://secwatch.observer/filing/0001193125-25-169947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/0001193125-25-169947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625297/000119312525169947/d908304d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:20:02.526590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}